Breaking News

Charles River Launches Rep/Cap Plasmids

Designed to streamline adeno-associated virus (AAV)-based gene therapy programs.

Charles River Laboratories has launched its off-the-shelf Rep/Cap plasmid offering designed to streamline adeno-associated virus (AAV)-based gene therapy programs. Following the previously announced launch of its lentiviral packaging and AAV Helper plasmid products, the addition of AAV Rep/Cap (RC2, 5, 6, 8, 9) supplements a comprehensive range of contract development and manufacturing organization (CDMO) products and services, and aims to reduce manufacturing effort by up to 66%. The read...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters